Journal
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
Volume 692, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.abb.2020.108546
Keywords
Pancreatic cancer; Colon cancer; Lung cancer; Epigallocatechin-3-gallate; Gemcitabine; 5-FU; Doxorubicin; ERK
Categories
Funding
- University of California, Davis
- NIFA-USDA [CA-D-NTR-2397-H]
- China Scholarship Council fellowship
- UC Davis Comprehensive Cancer Center [NCI P30CA093373]
- NSF
- UC Davis Comprehensive Cancer Center Support Grant (CCSG) [NCI P30CA093373]
Ask authors/readers for more resources
Epigallocatechin-3-gallate (EGCG), a major polyphenol component of green tea, presents anticancer efficacy. However, its exact mechanism of action is not known. In this study, we evaluated the effect of EGCG alone or in combination with current chemotherapeutics [gemcitabine, 5-flourouracil (5-FU), and doxorubicin] on pancreatic, colon, and lung cancer cell growth, as well as the mechanisms involved in the combined action. EGCG reduced pancreatic, colon, and lung cancer cell growth in a concentration and time-dependent manner. EGCG strongly induced apoptosis and blocked cell cycle progression. Moreover, EGCG enhanced the growth inhibitory effect of 5-FU and doxorubicin. Of note, EGCG enhanced 5-FU's and doxorubicin's effect on apoptosis, but not on cell cycle. Mechanistically, EGCG reduced ERK phosphorylation concentration-dependently, and sensitized gemcitabine, 5-FU, and doxorubicin to further suppress ERK phosphorylation in multiple cancer cell lines. In conclusion, EGCG presents a strong anticancer effect in pancreatic, colon, and lung cancer cells and is a robust combination partner for multiple chemotherapeutics as evidenced by reducing cancer cell growth, in part, by inhibiting the ERK pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available